Peter W. Szlosarek

Charterhouse Square
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort.

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort.

Journal: JCO precision oncology

Published: January 14, 2026

Intensive Surveillance and Aggressive Multimodal Treatment for Liver Metastases From Uveal Melanoma.

Intensive Surveillance and Aggressive Multimodal Treatment for Liver Metastases From Uveal Melanoma.

Journal: Annals of surgery open : perspectives of surgical history, education, and clinical approaches

Published: June 16, 2025

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Journal: Nature communications

Published: June 01, 2025

Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan-Induced DNA Double-Strand Breaks in Uveal Melanoma.

Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan-Induced DNA Double-Strand Breaks in Uveal Melanoma.

Journal: Pigment cell & melanoma research

Published: April 06, 2025

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Journal: Nature communications

Published: October 11, 2024

Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma.

Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma.

Journal: iScience

Published: April 18, 2024

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.

Journal: JAMA oncology

Published: February 15, 2024

Local tumour control and patient survival after ruthenium-106 brachytherapy for small choroidal melanoma.

Local tumour control and patient survival after ruthenium-106 brachytherapy for small choroidal melanoma.

Journal: The British journal of ophthalmology

Published: October 06, 2023

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.

Journal: Pharmacological reports : PR

Published: May 17, 2023

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.

Journal: Pharmacological reports : PR

Published: January 23, 2023

Bench-to-Bedside Studies of Arginine Deprivation in Cancer.

Bench-to-Bedside Studies of Arginine Deprivation in Cancer.

Journal: Molecules (Basel, Switzerland)

Published: December 31, 2022

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.

BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.

Journal: Molecular cancer research : MCR

Published: August 12, 2022

Showing 1-12 of 57

Last Updated: 09/26/2026